Clinical Trials Directory

Trials / Completed

CompletedNCT00928681

A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis

A Randomized, Double-Blind (Sponsor Open), Placebo Controlled, Dose Escalating, Parallel Group, Multi-Centre Study To Investigate The Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Single And Multiple Intravenous/Sub-Cutaneous Doses Of PF-00547659 In Patients With Active Ulcerative Colitis.

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
80 (actual)
Sponsor
Pfizer · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

study to investigate the safety and efficacy properties of PF-00547659 in patients with active ulcerative colitis

Conditions

Interventions

TypeNameDescription
BIOLOGICALSingle dose-group APF-00547659, single iv dose
BIOLOGICALSingle dose-group APF-00547659, single iv dose
BIOLOGICALMultiple dose- Group BPF-00547659, multiple dose
BIOLOGICALSingle dose-group APF-00547659, single iv dose
BIOLOGICALMultiple dose- Group BPF-00547659, multiple dose
BIOLOGICALSingle dose-group APF-00547659, single dose
BIOLOGICALSingle dose-group APF-00547659, single dose
BIOLOGICALSingle dose-group APF-00547659, single dose
BIOLOGICALSingle dose-group APF-00547659, single dose
BIOLOGICALMultiple dose-Group BPF-00547659, multiple dose
BIOLOGICALMultiple dose- Group BPF-00547659, multiple dose
BIOLOGICALMultiple dose- Group BPF-00547659, multiple dose
BIOLOGICALMultiple dose- Group BPF-00547659, multiple dose
BIOLOGICALMultiple dose- Group BPF-00547659, multiple dose
BIOLOGICALMultiple dose-Group BPF-00547659, multiple dose

Timeline

Start date
2005-09-01
Primary completion
2008-04-01
Completion
2008-10-01
First posted
2009-06-26
Last updated
2009-06-26

Locations

18 sites across 7 countries: Belgium, Czechia, Denmark, Germany, Norway, Slovakia, Spain

Source: ClinicalTrials.gov record NCT00928681. Inclusion in this directory is not an endorsement.